Life Sciences Tools & Services
Medpace Holdings Inc (MEDP)
SELL. 12-month probability-weighted target $523 (-15% vs spot). P/E Multiple explains 66% of Monte Carlo outcome variance.
Danaher Corporation (DHR)
SELL. 12-month probability-weighted target $191 (-13% vs spot). P/E Multiple explains 73% of Monte Carlo outcome variance.
Bio-Rad Laboratories Inc (BIO)
SELL. 12-month probability-weighted target $299 (-18% vs spot). Gross Margin explains 60% of Monte Carlo outcome variance.
Agilent Technologies Inc (A)
SELL. 12-month probability-weighted target $131 (-23% vs spot). P/E Multiple explains 73% of Monte Carlo outcome variance.
Waters Corporation (WAT)
SELL. 12-month probability-weighted target $359 (-17% vs spot). P/E Multiple explains 82% of Monte Carlo outcome variance.
Mettler-Toledo International Inc (MTD)
SELL. 12-month probability-weighted target $1228 (-21% vs spot). P/E Multiple explains 72% of Monte Carlo outcome variance.
Thermo Fisher Scientific Inc (TMO)
SELL. 12-month probability-weighted target $505 (-23% vs spot). P/E Multiple explains 67% of Monte Carlo outcome variance.
Charles River Laboratories (CRL)
SELL. 12-month probability-weighted target $206 (-32% vs spot). P/E Multiple explains 50% of Monte Carlo outcome variance.
IQVIA Holdings Inc (IQV)
SELL. 12-month probability-weighted target $186 (-28% vs spot). P/E Multiple explains 49% of Monte Carlo outcome variance.
Illumina Inc (ILMN)
SELL. 12-month probability-weighted target $179 (-36% vs spot). P/E Multiple explains 65% of Monte Carlo outcome variance.
Avantor Inc (AVTR)
SELL. 12-month probability-weighted target $10 (-34% vs spot). Gross Margin explains 63% of Monte Carlo outcome variance.
Bio-Techne Corp (TECH)
Rating suspended since 2026-10-12 — pending acquisition. The rating, price target and expected return are withheld until the name is re-valued; the research on the report page predates the review.